NR4A1 and breast carcinoma: A 2021 analysis of the PRAEGNANT prospective registry of advanced breast cancers found no significant difference in survival between HER2‐low vs HER2‐negative advanced triple‐negative breast cancers or in advanced hormone receptor–positive breast cancers.19